Main Article Content
Abstract
Tazarotene, the first of new generation receptor selective topical retinoid, currently being investigated and widely used in treatment of mild to moderate psoriasis. Objective: Effect of topical tazoretene in comparison to topical corticosteroids on serum proteins in chronic plaque psoriasis. Meterials and Methods: 50 patients of chronic plaque psoriasis enrolled in to the study, were divided into two groups of 25 each randomly. One group received once daily application of tazarotene gel and the other group received mometasone furoate cream once daily. Both the groups received treatment for 12 weeks. Serum protein levels were estimated at base line and at 12 weeks.
Results: Both tazarotene gel and mometasone cream were significantly effective. The baseline serum proteins were below normal in both the groups, which significantly increased after 12 weeks of treatment. However there was no significant difference between the two treatment groups on serum proteins.
Interpretation and Conclusion
Though mometasone furoate was found to be superior to tazarotene, it can still be used in place of corticosteroids for mild to moderate cases to overcome the well known adverse effects of corticosteroids.
Keywords
Article Details
References
- 1. Christophers E, Mrowietz U. Psoriasis. In: Freeberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editors. Fitzpatrick’s dermatology in general medicine. 6th Edn, Vol.1, New York: McGraw Hill; 2003. p.407-27.
- 2. Farber EM. The language of psoriasis. Int J Dermatol 1991; 30(4): 295-302.
- 3. Farber EM, Peterson JB. Variations in the natural history of psoriasis. Calif Med 1961; 95: 6-11.
- 4. Fry L. Psoriasis. Br J Dermatol 1988; 119: 445-61.
- 5. Pusey WA. History of dermatology. In: Charles C, editor. Springfield IL. 1933. p.223.
- 6. Camp RDR. Psoriasis. In: Champion RH, Burton JL, Burns DA, Breathnach SM, editors. Textbook of dermatology. 6th Edn. Vol.12, London: Blackwell Science; 1998. p.1589-649.
- 7. Eugene M, Palo AHO. History of treatment of psoriasis. J Am Acad Dermatol 1992; 4: 640-45.
- 8. Ronald M, Roxberg AC.Psoriasis.In: Roxberghs common skin disease. 17 Edn, Londen: Arnold 2003.p.128-42.
- 9. Lebwohl M, Alis. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45: 487-98.
- 10. Mehta TK, Shah RN, Marquis LA. Study of 300 cases of psoriasis. Indian J Dermatol Venereol Leprol 1976; 42(2): 67-69.
- 11. Kaur I, Kumar B, Sharma VK, Kaur S. Epidemiology of psoriasis in a clinic from North India. Indian J Dermatol Venereol Leprol 1986; 52: 208-12
- 12. Roenigh HH, Aurebach R, Maibach H. Methotrexate guidelines revised. J Am Acad Dermatol 1982; 6: 145-55.
- 13. Sharma TP, Sepaha GU. Psoriasis – A clinical study. Indian J Dermatol Venereol 1964; 30(5): 191-203.
- 14. Butaky L, Weinstein G. The therapy of moderate to severe psoriasis with methotrexate. In: Weinstein G, Gottlieb A, editors. National psoriasis foundation. Therapy of moderate to severe psoriasis. Harber and Flora Inc ; 1993. p.75-93. 105
- 15. Mills CM, Srivastav ED, Harvey IM, Swiff GL, Newcombe RG, Holt PS et al. Smoking habits in psoriasis a case control study. Br J Dermatol 1992; 127:18-21.
- 16. Naldi L, Peli L, Parazini F. Association of early – stage psoriasis with smoking and male alcohol consumption. Arch Dermatol 1999; 135: 1479-84.
- 17. Kantharaj GR, Srinivas CR, Devi PU, Ganasoundari A, Shenoy SD, Deshmukh RP et.al., Quantitative estimation and recommendation for supplementation of protein lost through scaling in exfoliative dermatitis. Int J Dermatol 1999;38:91-5.
- 18. Bos JD, Melinardi, Joost TV, Heule F, Powles AV, Fry L. Use of cyclosporine in psoriasis. The Lancet 1989; 23/30: 1500-03.
- 19. Moy RL, Timothy P, Kingston P, Lowe NJ. Isotretinoin Vs Etretinate therapy in generalized pustular and chronic psoriasis. Arch Dermatol 1985; 121: 1297-301.
- 20. Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Freidman DJ, Jegasothy BV et.al. Tazarotene gel, a new retinoid for topical therapy of psoriasis: vehicle controlled study of safety, efficacy and duration of therapeutic effect. J Am Acad Dermatol 1997; 37:85-92.
- 21. Lebwohl M, Ast E, Cullen SI, Hong SR, Kulpshorten CL et al. Once daily tazarotene gel verses twice daily flucinocide cream in treatment of plaque psoriasis. Am Acad Dermatol 1998; 38:705-11. 107.
References
1. Christophers E, Mrowietz U. Psoriasis. In: Freeberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editors. Fitzpatrick’s dermatology in general medicine. 6th Edn, Vol.1, New York: McGraw Hill; 2003. p.407-27.
2. Farber EM. The language of psoriasis. Int J Dermatol 1991; 30(4): 295-302.
3. Farber EM, Peterson JB. Variations in the natural history of psoriasis. Calif Med 1961; 95: 6-11.
4. Fry L. Psoriasis. Br J Dermatol 1988; 119: 445-61.
5. Pusey WA. History of dermatology. In: Charles C, editor. Springfield IL. 1933. p.223.
6. Camp RDR. Psoriasis. In: Champion RH, Burton JL, Burns DA, Breathnach SM, editors. Textbook of dermatology. 6th Edn. Vol.12, London: Blackwell Science; 1998. p.1589-649.
7. Eugene M, Palo AHO. History of treatment of psoriasis. J Am Acad Dermatol 1992; 4: 640-45.
8. Ronald M, Roxberg AC.Psoriasis.In: Roxberghs common skin disease. 17 Edn, Londen: Arnold 2003.p.128-42.
9. Lebwohl M, Alis. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45: 487-98.
10. Mehta TK, Shah RN, Marquis LA. Study of 300 cases of psoriasis. Indian J Dermatol Venereol Leprol 1976; 42(2): 67-69.
11. Kaur I, Kumar B, Sharma VK, Kaur S. Epidemiology of psoriasis in a clinic from North India. Indian J Dermatol Venereol Leprol 1986; 52: 208-12
12. Roenigh HH, Aurebach R, Maibach H. Methotrexate guidelines revised. J Am Acad Dermatol 1982; 6: 145-55.
13. Sharma TP, Sepaha GU. Psoriasis – A clinical study. Indian J Dermatol Venereol 1964; 30(5): 191-203.
14. Butaky L, Weinstein G. The therapy of moderate to severe psoriasis with methotrexate. In: Weinstein G, Gottlieb A, editors. National psoriasis foundation. Therapy of moderate to severe psoriasis. Harber and Flora Inc ; 1993. p.75-93. 105
15. Mills CM, Srivastav ED, Harvey IM, Swiff GL, Newcombe RG, Holt PS et al. Smoking habits in psoriasis a case control study. Br J Dermatol 1992; 127:18-21.
16. Naldi L, Peli L, Parazini F. Association of early – stage psoriasis with smoking and male alcohol consumption. Arch Dermatol 1999; 135: 1479-84.
17. Kantharaj GR, Srinivas CR, Devi PU, Ganasoundari A, Shenoy SD, Deshmukh RP et.al., Quantitative estimation and recommendation for supplementation of protein lost through scaling in exfoliative dermatitis. Int J Dermatol 1999;38:91-5.
18. Bos JD, Melinardi, Joost TV, Heule F, Powles AV, Fry L. Use of cyclosporine in psoriasis. The Lancet 1989; 23/30: 1500-03.
19. Moy RL, Timothy P, Kingston P, Lowe NJ. Isotretinoin Vs Etretinate therapy in generalized pustular and chronic psoriasis. Arch Dermatol 1985; 121: 1297-301.
20. Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Freidman DJ, Jegasothy BV et.al. Tazarotene gel, a new retinoid for topical therapy of psoriasis: vehicle controlled study of safety, efficacy and duration of therapeutic effect. J Am Acad Dermatol 1997; 37:85-92.
21. Lebwohl M, Ast E, Cullen SI, Hong SR, Kulpshorten CL et al. Once daily tazarotene gel verses twice daily flucinocide cream in treatment of plaque psoriasis. Am Acad Dermatol 1998; 38:705-11. 107.